Drawing for PEBIOR

USPTO serial 85965588

PEBIOR

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
CANTONE, KERI H
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PEBIOR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Camille M. Miller

CAMILLE M. MILLER COZEN O'CONNOR1900 MARKET STPHILADELPHIA, PA 19103-3527UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical preparations that modulate the immune system; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations for the treatment of oncology, inflammation, dermatology and ophthalmology diseases and illnessesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 22, 2014MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Aug 22, 2014ABN5ABANDONMENT - AFTER PUBLICATION—
Aug 20, 2014EXARTEAS EXPRESS ABANDONMENT RECEIVED—
May 22, 2014ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Apr 29, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 29, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 9, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 21, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 20, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 20, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 20, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 17, 2014ALIEASSIGNED TO LIE—
Feb 28, 2014PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Feb 27, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Feb 27, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 27, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 27, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 26, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 25, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 25, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2013GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Oct 2, 2013GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Oct 2, 2013CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Sep 26, 2013DOCKASSIGNED TO EXAMINER—
Jul 5, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 24, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance